Skip to main content
Explore URMC
menu

Ruth M. O'Regan, M.D.

Publications

Showing all 112 journal articles & 0 books available

Journal Articles

3/16/2021
Tolaney SM, Kalinsky K, Kaklamani V, D'Adamo DR, Aktan G, Tsai ML, O'Regan RM, Kaufman PA, Wilks ST, Andreopoulou E, Patt DA, Yuan Y, Wang G, Savulsky C, Xing D, Kleynerman E, Karantza V, Diab S. "Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2021 Mar 16; Epub 2021 Mar 16.

10/2020
Dudek AZ, Liu LC, Fischer JH, Wiley EL, Sachdev JC, Bleeker J, Hurley RW, Tonetti DA, Thatcher GRJ, Venuti RP, O'Regan RM. "Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy." Breast cancer research and treatment.. 2020 Oct 0; 183(3):617-627. Epub 2020 Jul 22.

10/2020
Zhao J, Meisel J, Guo Y, Nahta R, Hsieh KL, Peng L, Wei Z, O'Regan R, Li X. "Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+?and FOXP3+?immune cells in HER2-positive breast cancer treated with neoadjuvant therapies." Breast cancer research and treatment.. 2020 Oct 0; 183(3):599-606. Epub 2020 Jul 26.

9/30/2020
Anthony L, Atweh G, Bhatia R, Carey LA, Chang JC, Edelman MJ, Kantoff PW, Markham MJ, Messersmith W, Nelson EL, Oettel K, O'Regan R, Verschraegen CF, Vose JM. "Benchmarks for Academic Oncology Faculty." . 2020 Sep 30; :OP2000020. Epub 2020 Sep 30.

8/15/2020
Khuri FR, O'Regan RM. "Progress in breast cancer research amid the COVID-19 gloom." Cancer.. 2020 Aug 15; 126 Suppl 16:3809-3810.

8/15/2020
Anandan A, Sharifi M, O'Regan R. "Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer." Current treatment options in oncology.. 2020 Aug 15; 21(10):84. Epub 2020 Aug 15.

8/10/2020
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. "Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2020 Aug 10; 38(23):2610-2619. Epub 2020 May 29.

8/1/2020
Sharifi MN, Anandan A, Grogan P, O'Regan RM. "Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies." Cancer.. 2020 Aug 1; 126(15):3400-3416. Epub 2020 May 19.

7/23/2020
Hennes ER, Reed M, Mably M, Jared J, Bergsbaken JJ, Deming D, Callander N, O'Regan R. "Implementation of a chemotherapy stewardship process." American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.. 2020 Jul 23; 77(15):1243-1248.

4/2020
Gradishar WJ, Anderson BO, Abraham J, Aft R, Agnese D, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Krishnamurthy J, Lyons J, Marcom PK, Matro J, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Young JS, Burns JL, Kumar R. "Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : JNCCN.. 2020 Apr 0; 18(4):452-478.

3/1/2020
Zhang S, O'Regan R, Xu W. "The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics." Cancer.. 2020 Mar 1; 126(5):939-948. Epub 2019 Dec 23.

2/2020
Meisel JL, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. "Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer." Clinical breast cancer.. 2020 Feb 0; 20(1):19-24. Epub 2019 Sep 18.

12/17/2019
Fatima I, El-Ayachi I, Playa HC, Alva-Ornelas JA, Khalid AB, Kuenzinger WL, Wend P, Pence JC, Brakefield L, Krutilina RI, Johnson DL, O'Regan RM, Seewaldt V, Seagroves TN, Krum SA, Miranda-Carboni GA. "Simultaneous Multi-Organ Metastases from Chemo-Resistant Triple-Negative Breast Cancer Are Prevented by Interfering with WNT-Signaling." Cancers.. 2019 Dec 17; 11(12)Epub 2019 Dec 17.

9/15/2019
Meisel JL, O'Regan RM. "Race, breast cancer, and prognosis: Where biology is queen?" Cancer.. 2019 Sep 15; 125(18):3104-3106. Epub 2019 Jun 17.

8/2019
Arciero CA, Guo Y, Jiang R, Behera M, O'Regan R, Peng L, Li X. "ER/HER2 Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER/HER2 Breast Cancer." Clinical breast cancer.. 2019 Aug 0; 19(4):236-245. Epub 2019 Feb 14.

6/2019
Paplomata E, Zelnak A, Santa-Maria CA, Liu Y, Gogineni K, Li X, Moreno CS, Chen Z, Kaklamani V, O'Regan RM. "Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer." Clinical breast cancer.. 2019 Jun 0; 19(3):188-196. Epub 2019 Jan 03.

3/1/2019
El Ayachi I, Fatima I, Wend P, Alva-Ornelas JA, Runke S, Kuenzinger WL, Silva J, Silva W, Gray JK, Lehr S, Barch HC, Krutilina RI, White AC, Cardiff R, Yee LD, Yang L, O'Regan RM, Lowry WE, Seagroves TN, Seewaldt V, Krum SA, Miranda-Carboni GA. "The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer." Cancer research.. 2019 Mar 1; 79(5):982-993. Epub 2018 Dec 18.

2/2019
Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. "NCCN Guidelines Insights: Breast Cancer, Version 3.2018." Journal of the National Comprehensive Cancer Network : JNCCN.. 2019 Feb 0; 17(2):118-126.

1/15/2019
Kalinsky K, O'Regan RM. "Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?" Cancer.. 2019 Jan 15; 125(2):177-180. Epub 2018 Nov 02.

12/15/2018
Thompson MA, O'Regan RM. "Social media and clinical trials: The pros and cons gain context when the patient is at the center." Cancer.. 2018 Dec 15; 124(24):4618-4621. Epub 2018 Oct 19.

10/2018
Meisel J, Zhang C, Neely C, Mendoza P, You S, Han T, Liu Y, Sahin AA, O'Regan R, Li X. "Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score." Clinical breast cancer.. 2018 Oct 0; 18(5):347-352. Epub 2017 Dec 14.

8/2018
O'Regan RM, Nahta R. "Targeting forkhead box M1 transcription factor in breast cancer." Biochemical pharmacology.. 2018 Aug 0; 154:407-413. Epub 2018 May 31.

5/23/2018
Denduluri N, Miller K, O'Regan RM. "Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer." American Society of Clinical Oncology educational book. 2018 May 23; 38:47-55.

3/2018
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. "Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology." Journal of the National Comprehensive Cancer Network : JNCCN.. 2018 Mar 0; 16(3):310-320.

1/2018
Miller-Kleinhenz J, Guo X, Qian W, Zhou H, Bozeman EN, Zhu L, Ji X, Wang YA, Styblo T, O'Regan R, Mao H, Yang L. "Dual-targeting Wnt and uPA receptors using peptide conjugated ultra-small nanoparticle drug carriers inhibited cancer stem-cell phenotype in chemo-resistant breast cancer." Biomaterials.. 2018 Jan 0; 152:47-62. Epub 2017 Oct 21.

1/2018
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Cs?szi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T. "Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet. Oncology.. 2018 Jan 0; 19(1):87-100. Epub 2017 Dec 07.

2018
Shah R, O'Regan RM. "Adjuvant Endocrine Therapy." Cancer treatment and research.. 2018 173:15-29.

12/2017
Arciero CA, Yang J, Peng L, Ward KC, O'Regan R, Sahin AA, Li X. "African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages." Breast cancer research and treatment.. 2017 Dec 0; 166(3):743-755. Epub 2017 Aug 30.

8/2017
Li X, Yang J, Krishnamurti U, Huo L, Ward KC, O'Regan R, Peng L. "Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients." Clinical breast cancer.. 2017 Aug 0; 17(5):356-366. Epub 2017 Apr 28.

4/2017
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. "NCCN Guidelines Insights: Breast Cancer, Version 1.2017." Journal of the National Comprehensive Cancer Network : JNCCN.. 2017 Apr 0; 15(4):433-451.

2/24/2017
Rahim B, O'Regan R. "AR Signaling in Breast Cancer." Cancers.. 2017 Feb 24; 9(3)Epub 2017 Feb 24.

2/2017
Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ. "Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer." Investigational new drugs.. 2017 Feb 0; 35(1):87-94. Epub 2016 Nov 08.

1/2017
Li X, Yang J, Peng L, Sahin AA, Huo L, Ward KC, O'Regan R, Torres MA, Meisel JL. "Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer." Breast cancer research and treatment.. 2017 Jan 0; 161(2):279-287. Epub 2016 Nov 25.

11/2016
Tevaarwerk AJ, Wisinski KB, O'Regan RM. "Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer." Journal of oncology practice. 2016 Nov 0; 12(11):1148-1156.

6/20/2016
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. "Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2016 Jun 20; 34(18):2115-24. Epub 2016 Apr 18.

6/2016
Li XB, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O'Regan R, Aneja R. "Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer." American journal of clinical pathology.. 2016 Jun 0; 145(6):871-8. Epub 2016 Jun 12.

5/3/2016
Strauss WM, Carter C, Simmons J, Klem E, Goodman N, Vahidi B, Romero J, Masterman-Smith M, O'Regan R, Gogineni K, Schwartzberg L, Austin LK, Dempsey PW, Cristofanilli M. "Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkers." Oncotarget.. 2016 May 3; 7(18):26724-38.

3/2016
Rampurwala M, Wisinski KB, O'Regan R. "Role of the androgen receptor in triple-negative breast cancer." Clinical advances in hematology & oncology : H&O.. 2016 Mar 0; 14(3):186-93.

8/2015
Zelnak AB, O'Regan RM. "Optimizing Endocrine Therapy for Breast Cancer." Journal of the National Comprehensive Cancer Network : JNCCN.. 2015 Aug 0; 13(8):e56-64.

4/2015
Dietze EC, Sistrunk C, Miranda-Carboni G, O'Regan R, Seewaldt VL. "Triple-negative breast cancer in African-American women: disparities versus biology." Nature reviews. Cancer.. 2015 Apr 0; 15(4):248-54. Epub 2015 Feb 12.

3/10/2015
Taliaferro-Smith L, Oberlick E, Liu T, McGlothen T, Alcaide T, Tobin R, Donnelly S, Commander R, Kline E, Nagaraju GP, Havel L, Marcus A, Nahta R, O'Regan R. "FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells." Oncotarget.. 2015 Mar 10; 6(7):4757-72.

2/15/2015
Paplomata E, Nahta R, O'Regan RM. "Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?" Cancer.. 2015 Feb 15; 121(4):517-26. Epub 2014 Oct 24.

2/2015
Zelnak AB, Nikolinakos P, Srinivasiah J, Jonas W, Pippas A, Liu Y, Li X, Torres M, O'Regan RM, . "High pathologic complete response in Her2-positive, early-stage breast cancer to a novel nonanthracycline neoadjuvant chemotherapy." Clinical breast cancer.. 2015 Feb 0; 15(1):31-6. Epub 2014 Jun 24.

9/15/2014
Brawley OW, O'Regan RM. "Breast cancer screening: time for rational discourse." Cancer.. 2014 Sep 15; 120(18):2800-2. Epub 2014 Jun 12.

9/15/2014
Liu D, Xiong H, Ellis AE, Northrup NC, Rodriguez CO, O'Regan RM, Dalton S, Zhao S. "Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer." Cancer research.. 2014 Sep 15; 74(18):5045-56. Epub 2014 Jul 31.

8/1/2014
Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP. "Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2014 Aug 1; 32(22):2311-7. Epub 2014 Jun 16.

7/2014
Paplomata E, O'Regan R. "The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers." . 2014 Jul 0; 6(4):154-66.

5/2014
André F, O'Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, Yap YS, Papai Z, Lang I, Armstrong A, Lerzo G, White M, Shen K, Litton J, Chen D, Zhang Y, Ali S, Taran T, Gianni L. "Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial." The Lancet. Oncology.. 2014 May 0; 15(6):580-91. Epub 2014 Apr 14.

4/2014
Jacob Arriola KR, Mason TA, Bannon KA, Holmes C, Powell CL, Horne K, O'Regan R. "Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients." Patient education and counseling.. 2014 Apr 0; 95(1):98-103. Epub 2014 Jan 10.

2014
Xu J, Agyemang S, Qin Y, Aysola K, Giles M, Oprea G, O'Regan RM, Partridge EE, Harris-Hooker S, Rice VM, Reddy ES, Rao VN. "A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells." . 2014 1(1)

10/2013
Hurvitz SA, Dalenc F, Campone M, O'Regan RM, Tjan-Heijnen VC, Gligorov J, Llombart A, Jhangiani H, Mirshahidi HR, Tan-Chiu E, Miao S, El-Hashimy M, Lincy J, Taran T, Soria JC, Sahmoud T, André F. "A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy." Breast cancer research and treatment.. 2013 Oct 0; 141(3):437-46. Epub 2013 Oct 08.

8/2013
Paplomata E, Zelnak A, O'Regan R. "Everolimus: side effect profile and management of toxicities in breast cancer." Breast cancer research and treatment.. 2013 Aug 0; 140(3):453-62. Epub 2013 Aug 02.

7/25/2013
Hagen KR, Zeng X, Lee MY, Tucker Kahn S, Harrison Pitner MK, Zaky SS, Liu Y, O'Regan RM, Deng X, Saavedra HI. "Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis." Cell division. 2013 Jul 25; 8(1):10. Epub 2013 Jul 25.

6/2013
Zelnak AB, Styblo TM, Rizzo M, Gabram SG, Wood WC, Harichand-Herdt S, Kim S, Liu Y, O'Regan RM, . "Final results from phase II trial of neoadjuvant docetaxel and capecitabine given sequentially or concurrently for HER2-negative breast cancers." Clinical breast cancer.. 2013 Jun 0; 13(3):173-9. Epub 2013 Jan 16.

3/2013
Zelnak AB, O'Regan RM. "Genomic subtypes in choosing adjuvant therapy for breast cancer." Oncology.. 2013 Mar 0; 27(3):204-10.

2/1/2013
Habtes I, Friedman D, Raskind-Hood C, Adams K, Becker ER, D'Orsi C, Birdsong G, Gundry K, O'Regan R, Gabram SG. "Determining the impact of US mammography screening guidelines on patient survival in a predominantly African American population treated in a public hospital during 2008." Cancer.. 2013 Feb 1; 119(3):481-7. Epub 2012 Aug 01.

2013
Paplomata E, O'Regan R. "New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus." Therapeutics and clinical risk management.. 2013 9:27-36. Epub 2013 Jan 14.

2013
Marcus DM, Switchenko JM, Prabhu R, O'Regan R, Zelnak A, Fasola C, Mister D, Torres MA. "Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer." Frontiers in oncology.. 2013 3:317. Epub 2013 Dec 27.

11/20/2012
Shulman LN, Cirrincione CT, Berry DA, Becker HP, Perez EA, O'Regan R, Martino S, Atkins JN, Mayer E, Schneider CJ, Kimmick G, Norton L, Muss H, Winer EP, Hudis C. "Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2012 Nov 20; 30(33):4071-6. Epub 2012 Jul 23.

8/2012
Nahta R, O'Regan RM. "Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers." Breast cancer research and treatment.. 2012 Aug 0; 135(1):39-48. Epub 2012 Apr 20.

7/20/2012
Zhao P, Nairn AV, Hester S, Moremen KW, O'Regan RM, Oprea G, Wells L, Pierce M, Abbott KL. "Proteomic identification of glycosylphosphatidylinositol anchor-dependent membrane proteins elevated in breast carcinoma." The Journal of biological chemistry.. 2012 Jul 20; 287(30):25230-40. Epub 2012 May 31.

3/15/2012
Prabhu R, Godette K, Carlson G, Losken A, Gabram S, Fasola C, O'Regan R, Zelnak A, Torres M. "The impact of skin-sparing mastectomy with immediate reconstruction in patients with Stage III breast cancer treated with neoadjuvant chemotherapy and postmastectomy radiation." International journal of radiation oncology, biology, physics.. 2012 Mar 15; 82(4):e587-93. Epub 2011 Dec 22.

3/2012
O'Regan R. "Emerging nontaxane therapies for metastatic breast cancer." Clinical advances in hematology & oncology : H&O.. 2012 Mar 0; 10(3):187-9.

2/1/2012
Lund MJ, Mosunjac M, Davis KM, Gabram-Mendola S, Rizzo M, Bumpers HL, Hearn S, Zelnak A, Styblo T, O'Regan RM. "21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome." Cancer.. 2012 Feb 1; 118(3):788-96. Epub 2011 Jun 30.

2/2012
Gayle SS, Arnold SL, O'Regan RM, Nahta R. "Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance." Anti-cancer agents in medicinal chemistry.. 2012 Feb 0; 12(2):151-62.

2012
Mitri Z, Constantine T, O'Regan R. "The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy." Chemotherapy research and practice. 2012 2012:743193. Epub 2012 Dec 20.

12/15/2011
Andic F, Godette K, O'Regan R, Zelnak A, Liu T, Rizzo M, Gabram S, Torres M. "Treatment adherence and outcome in women with inflammatory breast cancer: does race matter?" Cancer.. 2011 Dec 15; 117(24):5485-92. Epub 2011 Jun 20.

10/2011
Zaky SS, Lund M, May KA, Godette KD, Beitler JJ, Holmes LR, O'Regan RM, Yu ES, Yu DS, Landry JC. "The negative effect of triple-negative breast cancer on outcome after breast-conserving therapy." Annals of surgical oncology.. 2011 Oct 0; 18(10):2858-65. Epub 2011 Mar 26.

8/2011
Liu T, Yacoub R, Taliaferro-Smith LD, Sun SY, Graham TR, Dolan R, Lobo C, Tighiouart M, Yang L, Adams A, O'Regan RM. "Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells." Molecular cancer therapeutics.. 2011 Aug 0; 10(8):1460-9. Epub 2011 Jun 20.

7/2011
O'Regan R, Hawk NN. "mTOR inhibition in breast cancer: unraveling the complex mechanisms of mTOR signal transduction and its clinical implications in therapy." Expert opinion on therapeutic targets.. 2011 Jul 0; 15(7):859-72. Epub 2011 Apr 08.

2/2011
O'Regan R. "Adjuvant anthracyclines: time for a change of heart?" Oncology.. 2011 Feb 0; 25(2):140, 142.

1/2011
Rizzo M, Bumpers H, Okoli J, Senior-Crosby D, O'Regan R, Zelnak A, Pan L, Mosunjac M, Patterson SG, Gabram SG. "Improving on national quality indicators of breast cancer care in a large public hospital as a means to decrease disparities for African American women." Annals of surgical oncology.. 2011 Jan 0; 18(1):34-9. Epub 2010 Jul 13.

12/1/2010
Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC, Naughton M, Hurvitz SA. "Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2010 Dec 1; 28(34):5110-5. Epub 2010 Oct 25.

12/2010
Harichand-Herdt S, O'regan RM. "Identifying subsets of metastatic breast cancer patients likely to benefit from treatment with the epothilone B analog ixabepilone." American journal of clinical oncology.. 2010 Dec 0; 33(6):561-7.

11/2010
Nahta R, O'Regan RM. "Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway." Clinical breast cancer.. 2010 Nov 0; 10 Suppl 3:S72-8.

8/2010
Graham TR, Yacoub R, Taliaferro-Smith L, Osunkoya AO, Odero-Marah VA, Liu T, Kimbro KS, Sharma D, O'Regan RM. "Reciprocal regulation of ZEB1 and AR in triple negative breast cancer cells." Breast cancer research and treatment.. 2010 Aug 0; 123(1):139-47. Epub 2009 Nov 18.

6/1/2010
Lund MJ, Butler EN, Hair BY, Ward KC, Andrews JH, Oprea-Ilies G, Bayakly AR, O'Regan RM, Vertino PM, Eley JW. "Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report." Cancer.. 2010 Jun 1; 116(11):2549-59.

3/2010
Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R. "In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells." Cancer chemotherapy and pharmacology.. 2010 Mar 0; 65(4):697-706. Epub 2009 Jul 28.

3/2010
Kaklamani VG, Cianfrocca M, Ciccone J, Kindy K, Rademaker A, Wiley EL, Gradishar W, O'Regan RM. "Increased HER2/neu expression in recurrent hormone receptor-positive breast cancer." Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.. 2010 Mar 0; 15(2):191-3.

2010
Iyengar R, Lund MJ, Lamson P, Holmes L, Rizzo M, Bumpers H, Okoli J, Senior-Crosby D, O'Regan R, Gabram SG. "Using National Quality Forum breast cancer indicators to measure quality of care for patients in an AVON comprehensive breast center." The breast journal.. 2010 16(3):240-4. Epub 2010 Apr 12.

12/2009
O'Regan RM. "Adjuvant chemotherapy: how much is enough?" The Lancet. Oncology.. 2009 Dec 0; 10(12):1132-3. Epub 2009 Nov 10.

9/2/2009
Rowe DL, Ozbay T, O'Regan RM, Nahta R. "Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin." Breast cancer : basic and clinical research.. 2009 Sep 2; 3:61-75. Epub 2009 Sep 02.

7/1/2009
Rizzo M, Lund MJ, Mosunjac M, Bumpers H, Holmes L, O'Regan R, Brawley OW, Gabram S. "Characteristics and treatment modalities for African American women diagnosed with stage III breast cancer." Cancer.. 2009 Jul 1; 115(13):3009-15.

2/2009
Harichand-Herdt S, Zelnak A, O'Regan R. "Endocrine therapy for the treatment of postmenopausal women with breast cancer." Expert review of anticancer therapy.. 2009 Feb 0; 9(2):187-98.

1/2009
Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW. "Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA." Breast cancer research and treatment.. 2009 Jan 0; 113(2):357-70. Epub 2008 Mar 07.

1/2009
Yezhelyev M, Yacoub R, O'Regan R. "Inorganic nanoparticles for predictive oncology of breast cancer." Nanomedicine.. 2009 Jan 0; 4(1):83-103.

12/1/2008
Saxena NK, Taliaferro-Smith L, Knight BB, Merlin D, Anania FA, O'Regan RM, Sharma D. "Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor." Cancer research.. 2008 Dec 1; 68(23):9712-22.

7/16/2008
Yezhelyev MV, Qi L, O'Regan RM, Nie S, Gao X. "Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging." Journal of the American Chemical Society.. 2008 Jul 16; 130(28):9006-12. Epub 2008 Jun 21.

4/1/2008
Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM. "Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells." Cancer research.. 2008 Apr 1; 68(7):2479-88.

4/2008
Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, Wells L, Tiemeyer M, Pierce M. "Targeted glycoproteomic identification of biomarkers for human breast carcinoma." Journal of proteome research.. 2008 Apr 0; 7(4):1470-80. Epub 2008 Feb 14.

2008
Zelnak AB, O'Regan R. "Adjuvant hormonal therapy for early-stage breast cancer." Cancer treatment and research.. 2008 141:63-78.

12/2007
Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A, Gradishar WJ. "A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience." Cancer investigation.. 2007 Dec 0; 25(8):733-7. Epub 2007 Oct 18.

1/2007
Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, Moriarty RM, Wood WC, Lee HY, Yang L. "Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells." Molecular pharmacology.. 2007 Jan 0; 71(1):101-11. Epub 2006 Oct 11.

2007
Xing Y, Chaudry Q, Shen C, Kong KY, Zhau HE, Chung LW, Petros JA, O'Regan RM, Yezhelyev MV, Simons JW, Wang MD, Nie S. "Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry." Nature protocols.. 2007 2(5):1152-65.

2007
Zelnak AB, O'Regan RM. "Targeting angiogenesis in advanced breast cancer." BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2007 21(4):209-14.

12/2006
Seleverstov O, Zabirnyk O, Zscharnack M, Bulavina L, Nowicki M, Heinrich JM, Yezhelyev M, Emmrich F, O'Regan R, Bader A. "Quantum dots for human mesenchymal stem cells labeling. A size-dependent autophagy activation." Nano letters.. 2006 Dec 0; 6(12):2826-32.

8/2006
Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. "Emerging use of nanoparticles in diagnosis and treatment of breast cancer." The Lancet. Oncology.. 2006 Aug 0; 7(8):657-67.

4/29/2006
O'Regan RM. "Chemoprevention of breast cancer." Lancet.. 2006 Apr 29; 367(9520):1382-3.

4/1/2006
O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC. "Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2006 Apr 1; 12(7 Pt 1):2255-63.

3/2006
Al-Hajj A, O'Regan R. "Selection of optimal adjuvant endocrine therapy for early-stage breast cancer." Current treatment options in oncology.. 2006 Mar 0; 7(2):153-65.

2006
O'Regan R. "Review: bisphosphonates prevent or delay skeletal events in women with advanced breast cancer and bone metastases." ACP journal club.. 2006 144(2):39.

6/2005
O'Regan RM, Von Roenn JH, Carlson RW, Malik U, Sparano JA, Staradub V, Khan S, Jovanovic B, Morrow M, Gradishar WJ. "Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer." Clinical breast cancer.. 2005 Jun 0; 6(2):163-8.

2005
Kudachadkar R, O'Regan RM. "Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer." CA: a cancer journal for clinicians.. 2005 55(3):145-63.

2005
Kim G, O'regan R, Nie S. "Biomedical nanotechnology for molecular imaging, profiling, and drug targeting." Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society.. 2005 2006:714-6.

9/1/2004
O'Regan RM. "Do tumors detected by mammography screening have a favorable prognosis?" JAMA.. 2004 Sep 1; 292(9):1062-3.

4/2004
Kaklamani V, O'Regan RM. "New targeted therapies in breast cancer." Seminars in oncology.. 2004 Apr 0; 31(2 Suppl 4):20-5.

2004
Zelnak AB, O'Regan RM. "Chemoprevention of breast cancer." Current problems in cancer. 2004 28(4):201-17.

12/2003
Shah AP, Parmar S, O'Regan R. "Right atrial and ventricular thrombus infiltrated with osteoblastic osteosarcoma." Journal of cardiovascular pharmacology and therapeutics.. 2003 Dec 0; 8(4):307-11.

8/2003
Gradishar WJ, O'Regan RM. "Progress in systemic adjuvant therapy of early-stage breast cancer." International journal of clinical oncology / Japan Society of Clinical Oncology. 2003 Aug 0; 8(4):239-47.

6/2002
Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC. "Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2002 Jun 0; 8(6):1995-2001.

4/2002
O'Regan RM, Jordan VC. "The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators." The Lancet. Oncology.. 2002 Apr 0; 3(4):207-14.

2/20/2002
O'Regan RM, Gajdos C, Dardes RC, De Los Reyes A, Park W, Rademaker AW, Jordan VC. "Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice." Journal of the National Cancer Institute.. 2002 Feb 20; 94(4):274-83.